ADTX - Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves
- Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product
- Aditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab –to offer AditxtScore(TM)
- This announcement comes amid reports warning of a fall and winter COVID-19 wave occasioned by waning immunity or a possible “nasty new variant”
- Already, the U.S. is undergoing a sixth wave even before the start of the summer
During the one week to May 18, the U.S. averaged roughly 100,000 COVID-19 cases each day, representing an increase of more than 3x from the lowest figure reported in March, yet the numbers did not include at-home test results, according to a Washington Post article. The piece quotes experts’ assumptions that the infections in their communities are five to ten times the official counts (https://ibn.fm/QgkXo).
Despite the disparity in the reported figures, the sheer number of infections is still a cause for concern, with White House health officials urging Americans to stay up-to-date with vaccines and booster shots, get...
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.